Sunshine Biopharma (SBFM) - Long-Term Debt to Capital

Corporate emblem and logo of Sunshine Biopharma, Inc. (SBFM)

Sunshine Biopharma (SBFM) delegates drug development and testing to third-party partners, maintaining a lean scientific staff without in-house manufacturing facilities. This price chart reflects the 0.02 metric. The business model is based on contract molecule production in North America, which eliminates the risk of capacity downtime. Utilizing multiple external laboratories for synthesis and research minimizes fixed costs and removes dependency on a single contractor.

Sunshine Biopharma - SBFM Long-Term Debt to Capital (period 07/04/2022 - 10/30/2026)

Analytical breakdowns for Sunshine Biopharma

- stock value and consensus price forecast:
Stock Quotes sunshinebiopharma.com|SBFM - Analyst Consensus Forecast
- market capitalization indicators:
Market Capitalization Sunshine Biopharma, Inc.|SBFM - Total Company Value
- company book value details:
Equity per Share Sunshine Biopharma|SBFM - Book Capitalization|Market Cap to Net Assets Ratio sunshinebiopharma.com|SBFM - Company Total Assets
- company liabilities and liquidity data:
Debt to Capital Sunshine Biopharma|SBFM - Long-Term Debt to Equity|Ratio of Short-Term Indebtedness to Capital Sunshine Biopharma Inc.|SBFM - Company Total Debt|Debt to Net Assets Ratio Sunshine Biopharma, Inc.|SBFM - Company Long-Term Debts|Company Current Liabilities Sunshine Biopharma|Quick Ratio sunshinebiopharma.com
- financial results and valuation multiples details:
SBFM - Company Net Income
General company analysis:sunshinebiopharma.com - SBFM
Original product of sunshinebiopharma.com

Evaluating the stability of Sunshine Biopharma (SBFM), I am focusing on the long-term financing structure. This metric compares liabilities with maturities exceeding one year against equity to determine the degree of financial leverage. An analysis of the long-term debt-to-equity ratio reveals the risk of excessive debt service. For Sunshine Biopharma, this indicator is critical during a period of declining R&D activity. A low debt load currently ensures the company's survival during the lull in the development of mRNA assets.

Key competitors

Long-Term Debt to Equity Ratio BeiGene Ltd. (ONC)|Long-Term Debt to Capital HALO|Long-Term Debt to Capital Revolution Medicines Corp (RVMD)|Long-Term Debt to Equity Ascentage Pharma Group AAPG|CGON: Long-Term Debt to Capital Ratio|UroGen Pharma - Long-Term Debt to Capital|Bicara Therapeutics Inc (BCAX) - Long-Term Debt to Equity Ratio|PSNL: Long-Term Debt to Capital|Long-Term Liabilities to Capital Erasca Oncology (ERAS)|Long-Term Debt to Equity Delcath Systems, Inc.|YMAB: Long-Term Debt to Capital Coefficient|Long-Term Debt to Equity Ratio AURA (Aura Biosciences)|CADL (candeltx.com) - Long-Term Debt to Capital Coefficient|Long-Term Debt to Capital ARAY (Accuray Inc.)|SLS - Long-Term Debt to Equity Ratio|ACTU: Long-Term Debt to Equity Ratio|CTOR - Long-Term Debt to Capital|tuhurabio.com (HURA) - Long-Term Debt to Equity|Protara Therapeutics Inc - Long-Term Debt to Capital Coefficient|FATE (Fate Therapeutics Corp) - Long-Term Debt to Capital|Long-Term Liabilities to Capital Aadi Bio WHWK|Long-Term Debt to Equity TScan Therapeutics (TCRX)|Ratio of Long-Term Indebtedness to Capital championsoncology.com|XBiotech - Long-Term Debt to Equity Ratio|Long-Term Debt to Capital CEL-SCI Corp. CVM|OSTX - Long-Term Debt to Equity|RADX (Radiopharm Theranostics Ltd) - Long-Term Debt to Capital Ratio|artivabio.com (ARTV) - Long-Term Debt to Equity|ANL - Ratio of Long-Term Indebtedness to Capital|VERU (Veru) - Long-Term Debt to Capital|TPST: Long-Term Debt to Capital Coefficient|Long-Term Debt to Capital XLO|Ratio of Long-Term Indebtedness to Capital renovarobio.com|Long-Term Debt to Equity Mural Oncology MURA|KAPA: Long-Term Debt to Capital Ratio|OnKure - Long-Term Debt to Capital|Long-Term Liabilities to Capital CytoMed Therapeutics|CRIS (curis.com) - Long-Term Debt to Equity Ratio|Apollomics - Long-Term Debt to Capital Coefficient|THAR (Tharimmune, Inc.) - Long-Term Debt to Capital|Long-Term Debt to Equity ADVB|Long-Term Debt to Capital GNPX|Ratio of Long-Term Indebtedness to Capital calidibio.com|Long-Term Debt to Equity Xenetic Biosciences, Inc. XBIO|Salarius Pharma (SLRX) - Long-Term Liabilities to Capital|PPBT - Long-Term Debt to Equity|Long-Term Liabilities to Equity AONC|BGNE: Long-Term Debt to Capital|Checkpoint Therapeutics Inc. - Long-Term Debt to Capital Coefficient|ELEV (Elevation Oncology, Inc.) - Long-Term Debt to Capital|Long-Term Debt to Capital iCAD Corp|Long-Term Debt to Equity Ikena Oncology, Inc. (IKNA)|NTBL (notablelabs.com) - Long-Term Debt to Capital Coefficient|Long-Term Debt to Equity Viracta Therapeutics, Inc. VIRX|MOR - Long-Term Debt to Equity Ratio|NAYA Bio - Long-Term Debt to Capital|AAPGV - Long-Term Debt to Capital